OBJECTIVE To develop an effectual method for treating hepatic metastasis from rectal cancer. METHODS A randomized control study of celiac artery perfusion plus transcatheter hepatic arterial chemoembolization (TACE) (observation group) and intravenous chemotherapy (control group) for 99 cases with hepatic metastasis from rectal cancer was performed. The perfusion was repeated once at 4 weeks after the first treatment of 52 cases in the observation group, and it was subsequently repeated at an interval of 2 or 3 months. Using intravenous administration, the perfusion was repeated once every 3 weeks with 47 cases in the control group. RESULTS Three months after treatment, the patients in the observation group who showed a relief or elimination of a former superior abdominal pain amounted to 70.6%, and those with a diminution of their intrahepatic mass reached 55.8%. In the control group, the patients with a relief or disappearance of hepatalgia reached 20%, and those with a diminution of their intrahepatic mass reached 10.6%. The 1, 2 and 3-year survival rates were 80.8%, 46.2% and 25.0% in the cases of the observation group and 61.7%, 19.1% and 4.3% in the control group, respectively. CONCLUSION For the patients who failed to receive a surgical operation on their hepatic metastasis from rectal cancer, celiac artery perfusion plus TACE is a more effective regimen for improvement of the clinical symptoms and extension of the survival time, compared to intravenous chemotherapy, and is a better choice for palliative therapy.
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Hepatic metastasis is the major factor affecting the prognosis of patients with colorectal carcinoma. It has been reported that hepatic metastases occur in approximately 25% of colorectal carcinoma patients at the time of final diagnosis [1] [2] . Secondary hepatic metastasis might finally occur in 50 to 70% of the cases with a radical excision [3] [4] [5] . Without treatment, the mean survival time of patients was only 4.5 months following hepatic metastasis from colorectal carcinoma [6] . Our study was designed to examine the therapeutic effect of regional arterial perfusion chemotherapy of the liver on hepatic metastasis from rectal cancer in patients who failed to receive a surgical operation on the metastasis. A comparison was conducted between randomized celiac artery perfusion plus hepatic artery iodinated-oil emulsifying chemoembolization and simple intravenous chemotherapy on the patients with rectal cancer hepatic metastasis.
MATERIALS AND METHODS

Case information
A total of 413 patients with rectal cancer underwent a colorectal surgical operation in our hospital, from January 1991 to December 2001, among which 157 were found to have hepatic metastasis before and after surgery. Of these 157 patients, 134 lost an opportunity for resection of the hepatic metastasis. The patients' age ranged from 30 to 70 years and basically had normal liver function. They were randomly enrolled either into a group treated with celiac artery perfusion plus hepatic artery iodinated-oil emulsifying chemoembolization (hereafter as the observation group) or a group receiving intravenous chemotherapy (hereafter as the control group).
There were 52 cases in the observation group, with 29 males and 23 females. Their ages ranged from 32 to 65 with a mean of 56. Pre-and postoperative metastases were found in 22 and 30 cases respectively. Forty-nine of the patients received an excision of a primary focus, and 25 patients in the group were identified with a history of chemotherapy before hepatic metastasis. The number of individual hepatic metastasis per case was 2 to 7, averaging 3.5. The minimum diameter of each metastasis was 2.0 cm and the maximum 10.5 cm.
There were 47 patients in the control group, with 27 males and 20 females.The ages ranged from 34 to 69, with a mean of 57 years. Pre-and postoperative metastases were found in 19 and 28 cases respectively. Forty-six of these patients received an excision of the primary focus, and 21 patients were identified with a history of chemotherapy before hepatic metastasis. The number of individual hepatic metastasis per case was 2 to 8, averaging 3.8. The minimum diameter of each metastasis was 2.0 cm and the maximum 9.5 cm. A rigorous 5-year follow-up was conducted for all the cases. Adverse effects, side reactions and survival rates of the patients with liver metastasis between the 2 groups were compared.
Treatment method
A Seldinger catherterization was used for femoral arteriopuncture and intubatiuon in the observation group, and a celiac arteriogram was conducted via the catheter. After confirmation of an intrahepatic lesion, 30 mg of adriamycin (ADM), 1,000 mg 5-fluoro-2' -deoxy-β-uridine (FUDR) and 300 mg of carboplatin (CBP) were administered using celiac artery perfusion. The catheter was then put into the proper hepatic artery or left and right hepatic arteries to infuse 10 mg of ADM and 3 to 20 ml of an iodinatedoil mixed emulsion. A second interventional therapy was performed after a 1-month interval. Succedent hepatic arterial chemoembolization and perfusion was conducted every 2 to 3 months afterwards, until the treatment failed, based on a CT examination of the residual iodinated oil in the diseased region.
An internal jugular vein intubation was employed for the intravenous chemotherapy regimen in the control group, using the drugs as follows: 40 mg of ADM was infused on day one; 200 mg of CF and 500 mg of 5-FU were infused from day 1 to 5, respectively, and 400 mg of CBP was given on day 8. The regimen was repeated following a 3-week rest, until there was treatment failure.
Statistical treatment
The χ 2 test was conducted for enumeration data, the t test for measurement data and the life table for calculation of the survival rate, using SPSS 9.0 for windows.
RESULTS
The clinical data showed no significant differences prior to treatment between the observation and control groups (Table 1 , mean P value > 0.05), which provided a basis for comparing the therapeutic results. Table 2 shows a comparison of the adverse effects between the observation and control groups after treatment. Symptoms of various degrees such as nausea and vomiting, hypodynamia and anorexia, occurred in both groups. However, the duration of symptoms was shorter in the observation group compared to the control group. Hepatic gas pain, with fever and alteration of the liver function, occurred in most patients of the observation group with the incidence of these symptoms being much higher than the control group. However, these symptoms were basically relieved by 10 days. The incidence of WBC suppression was higher in the control group, compared to the observation group. Therapeutic efficacy A comparison of the therapeutic efficacy between the observation and control groups is shown in Table  3 . After treatment, the remission rate of the former symptoms in the hepatic region was significantly greater in the observation group compared to the control group. Three months after treatment, hepatic metastases were somewhat minimized in 55.8% of the observation-group patients, compared to the former condition, and those without metastatic augmentation amounted to 26.9%, providing a total effective rate of 82.7%. The median time of steady metastasis was 11 months in all cases of this group. The 1, 2 and 3-year survival rates were 80.8%, 46.2% and 25% respectively, and the median survival time was 22 months. Among these cases, disappearance of an intrahepatic mass was found in one case, with a survival time of over 60 months. During the follow-up, secondary intrahepatic metastases were detected in 18 cases, accounting for 34.6%. In the control group, 3 months after treatment, hepatic metastases were minimized, compared to the former condition, and those without a tendency of growth amounted to 29.8%, with a total effective rate of 40.4%. The median time of steady metastasis was 6 months in all cases of this group. The 1, 2 and 3-year survival rates were 61.7%, 19.1% and 4.3%, respectively and the median survival time was 13 months. No patients in this group were alive at 5 years after operation. Therefore, it was clear that the curative efficacy in the observation group was greater than that in the control group. During the follow-up, there was no significant difference between the 2 groups in secondary intrahepatic metastasis between the 2 groups. 
Adverse effects
DISCUSSION
Owing to the biological character of rectal cancer and the anatomic characteristics of the rectal venous return, the liver is readily involved in the hematogenic metastasis from rectal cancer [1] . In our study of 413 rectal cancer cases, hepatic metastatic carcinoma occurred in 157 (38.0%). A preoperative final diagnosis was made in 67 (16.2%), and postoperative secondary cases accounted for 90 (26.0%). Following the surgical operation, 92.2% (83/90) of the hepatic metastasis occurred within 3 years, and the incidence of metastasis 3 years after postoperation was only 7.8%, which is in accordance with reports in the literature [7] . A large dose of chemotherapeutic agents was directly perfused at the tumor site through a hepatic arterial cannula, thus lowering the opportunity for the drugs to bind with the plasma proteins and thereby greatly increasing the drug concentration within and around the tumor [8] . Superselective iodinated-oil emulsifying embolization allowed the oil to enter the tumor blood vessels and thus accumulate in the tumor for an extended time, completely embolizing the vessel resulting in tumor ischemia and necrosis. At the same time, the cancer cells underwent a permanent effect of a high-concentration of chemotherapeutic agents resulting in a more powerful lethal effect on the tumor cells [9] .
Yamamura et al. [10] conducted hepatic arterial cannula chemotherapy on 43 patients with hepatic metastasis who had no surgical opportunity. The effective rate was 41%, and the median survival time 13 months. Tarazov et al. [11] reported that iodinated oil, gelatin sponge and ADR chemoembolization was used for treatment of 67 cases with hepatic metastasis from colorectal carcinoma. The 1-year survival rate was 77%, and median survival time 12 months.
In our study of hepatic metastasis from rectal cancer, after a 3-month celiac artery perfusion plus hepatic artery iodinated-oil emulsifying chemoembolization, metastases were apparently minimized in 55% of the cases. No tendency of increased metastasis was found in 26.9% of the cases, and the total effective rate was overtly higher compared to patients receiving intravenous chemotherapy (82.7% vs 40.4%, χ 2 = 18.8, p < 0.01). The median time of stable hepatic metastasis was clearly longer in patients of the observation group than those of the control group (11 months vs 6 months, t = 5.01, P < 0.01). The median survival time was 22 months in the observation group, which was significantly longer compared to the 13 months of the control group ( t = 3.05, p < 0.05), and the 1, 2 and 3-year survival rates were significantly higher, compared to those in the control group (i.e. 80.8%, 46.2% and 25% vs 61.7%, 19.1% and 4.3%, P value < 0.05). These survival rates also were higher compared to the patients receiving a simple perfusion treatment via the hepatic artery, as reported by Yamamura et al., [10] and the simple hepatic artery embolism by Tarazov et al. [11] Our results showed that patients still can achieve the same therapeutic result with celiac artery perfusion plus a hepatic artery iodinated-oil emulsifying chemoembolization, regardless of their past chemotherapy history. Although the medicinal regimen has been adjusted, the integral therapeutic efficacy remained lower compared to those without past chemotherapy, if intravenous chemotherapy was still to be conducted.
With a prolongation of the course of disease, the ratio of tumor diminution was gradually lowered following repeated application of interventional therapy. Although there was a gradual blocking of the blood vessels in the tumor area, and vascular endothelial cell degeneration occurred, a compensatory circulation around the tumor gradually formed. Thus the sensitivity to the perfusion was decreased and tumorous proliferation occurred with a rise in the CEA over a period of time. This may relate to an increased tolerance of the tumor cells to the chemotherapeutic agent and a gradually emerging drug resistance. During the interventional therapy, intrahepatic secondary metastases rose up to 36.5%, which were higher compared to the 31.9% in the group receiving intravenous chemotherapy, perhaps because the concentration of the agents in the blood was lower in other organs compared to the group receiving intravenous chemotherapy. However, no statistically significant difference was found between the 2 groups (χ 2 = 0.23, p > 0.05).
Regarding the improvement of clinical symptoms and toxic effects after treatment, the improvement of the patient's hepatic hidden pain was clearly superior in the observation group compared to the control group (χ 2 = 8.18, p < 0.01), and the quality of life was significantly improved. There was no significant difference between the toxic effects of the chemotherapeutics, such as nausea, vomiting, debility and anorexia etc., and there was no significant difference between incidence of the toxic effect caused by the chemotherapeutic agents and intravenous chemotherapy (mean p value > 0.05), but the duration was decreased (χ 2 = 5.5, p < 0.05). In the observation group, the incidence of drug-related fever was significantly higher compared to the control group. In general, the low-grade fever required no special treatment and most patients returned to normal 2 to 3 days later. However, for some of the patients with a higher body temperature, 5 to 10 mg of dexamethasone was intravenously administered for 2 or 3 days, and at the same time, antibiotics were given to prevent infections. After hepatic arterial perfusion, serum transaminase and bilirubin increased more frequently compared to the control group. In general, these levels returned to normal by 2 weeks. Bone marrow depression was significantly lower in the observation group compared to the control group.
This study showed that celiac artery perfusion plus hepatic artery iodinated-oil emulsifying chemoembolization is a safe and effective palliative therapy method for inoperable patients with a hepatic metastasis from rectal cancer. This therapy can significantly improve the patients' quality of life and the 3-year survival rate. The curative effect of the treatment is superior to that of systemic intravenous chemotherapy, as well as better than simple hepatic arterial perfusion or embolization. It will remain effective for patients with or without a past history of chemotherapy, but fail to change the final patient outcome.
